Migraine Science
Placebo vs Nocebo Effect on Migraine Treatment
Stay in the Loop on the Latest in Migraine:
| Category | Placebo Effect | Nocebo Effect |
|---|---|---|
| Definition | An inactive treatment that leads to improvement in migraine due to positive patient expectations. | A treatment (inactive or active) that leads to worsening of migraine or the presence of adverse effects due to negative patient expectations. |
| Incidence in clinical trials | Up to 32.4% for acute treatments Up to 30.4% for preventives |
Up to 18.4% for acute treatments Up to 47% for preventives |
| Enhancing Factors | Positive doctor-patient relationship, parenteral route (especially surgery), specific drug mechanisms, branding/marketing, prior positive experiences. | Psychiatric comorbidities, chronic migraine, prior treatment failures, generic medications, observation of side effects in others. |
| Psychological Basis | Expectation of benefit, motivation, and reward circuits. | Expectation of harm, fear, and avoidance circuits. |
| Physiological Basis | Activation of descending pain pathways and dopamine reward circuits in the brain. | Increased activity in brain regions processing fear, anxiety and pain sensations. |
| Clinical Importance | Maximizing placebo can improve patient outcomes and treatment effectiveness. | Minimizing nocebo can improve patient outcomes and treatment compliance. |
| Modifiability | Can be enhanced through empathy, reassurance, positive framing by healthcare providers. | Can be minimized through empathy, reassurance about side effects, careful adverse event reporting. |
Where to next?
Pick a topic and dive into more free, research-backed guides in the Migraine Resource Hub.
Vestibular Rehabilitation for Vestibular Migraine: What 7 Studies Show
Seven studies and 272 adults with vestibular migraine show a pooled 23.97 point drop in dizziness handicap after vestibular rehabilitation, above the usual threshold for clinical meaningfulness. Balance confidence did...
Read More
Botox for Chronic Migraine: What 479 Real-World Patients Show
A 479-patient real-world study of onabotulinumtoxinA for chronic migraine found a mean reduction of 5.9 monthly headache days, with 27.3% reaching the 50% response threshold and 41.6% shedding medication overuse....
Read More
The New Migraine Prevention Guideline: What the AAN and AHS Recommend
The American Academy of Neurology and the American Headache Society have published a joint practice guideline on migraine prevention in adults: 17 recommendations and 52 statements. It names no single...
Read More
